Zevra Therapeutics, Inc. (FRA:1GDA)

Market Cap	426.47M +2.6%
Revenue (ttm)	71.92M +244.6%
Net Income	25.58M
EPS	0.46
Shares Out	n/a
PE Ratio	16.67
Forward PE	18.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	200
Open	7.65
Previous Close	7.75
Day's Range	7.65 - 7.65
52-Week Range	5.75 - 10.80
Beta	n/a
RSI	47.10
Earnings Date	Mar 6, 2026

About Zevra Therapeutics

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical tria...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1GDA

Financial Performance

In 2024, Zevra Therapeutics's revenue was $23.61 million, a decrease of -14.02% compared to the previous year's $27.46 million. Losses were -$105.51 million, 129.1% more than in 2023.

Financial numbers in USD